Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group
- PMID: 2188826
- DOI: 10.2165/00003495-199000392-00013
Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group
Abstract
The long acting angiotensin-converting enzyme inhibitor enalapril was compared with the calcium channel blocker nifedipine as sustained-release formulation in 136 patients with mild to moderate hypertension. This multicentre study was carried out in a double-blind, double-dummy fashion by 28 cardiologists in private practice. After a 2-week placebo period, patients were randomly allocated to 2 treatment groups; the first group received enalapril 20 mg daily (n = 68), and the second group received sustained-release nifedipine 20 mg twice daily (n = 68). The duration of treatment was 12 weeks. In both groups, hydrochlorothiazide 25 mg was added at week 4 if diastolic blood pressure remained greater than 90 mm Hg. At week 8, if the target diastolic pressure of less than 90 mm Hg was not achieved, the dosage of hydrochlorothiazide was increased to 50mg. The clinical characteristics of the patients in each group were comparable. After 4 weeks of treatment, the reduction in supine diastolic blood pressure was similar in both groups (12.1 mm Hg in the enalapril group vs 10.3 mm Hg in the nifedipine group). Moreover, although the difference between the groups was more noticeable after 12 weeks of treatment (16.3 vs 13.9 mm Hg, respectively), it did not reach significance. The number of patients experiencing clinical adverse effects was significantly greater in the nifedipine group than in the enalapril group [33 (48.5%) vs 18 (26.5%), respectively]. The most common complaints of patients administered nifedipine included swollen ankles, flushing and headaches, whereas complaints in the enalapril group included cough, asthenia, and epigastralgia. Three patients were withdrawn from the study because of side effects in the enalapril group and 10 were withdrawn from the nifedipine group. These results indicate that enalapril and sustained-release nifedipine are equally effective in controlling mild to moderate hypertension. However, enalapril was much better tolerated in this study.
Similar articles
-
[A randomized double-blind therapeutic trial of enalapril versus timed-release nifedipine in mild to moderate essential hypertension].Presse Med. 1990 Jan 6-13;19(1):13-6. Presse Med. 1990. PMID: 2137218 Clinical Trial. French.
-
Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison.Br J Clin Pharmacol. 1990 Aug;30(2):203-11. doi: 10.1111/j.1365-2125.1990.tb03766.x. Br J Clin Pharmacol. 1990. PMID: 2206783 Free PMC article. Clinical Trial.
-
Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial.J Cardiovasc Pharmacol. 1987;10 Suppl 10:S96-8. J Cardiovasc Pharmacol. 1987. PMID: 2455154 Clinical Trial.
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
-
Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.Am J Cardiovasc Dis. 2024 Dec 15;14(6):396-413. doi: 10.62347/RPMZ6407. eCollection 2024. Am J Cardiovasc Dis. 2024. PMID: 39839565 Free PMC article. Review.
Cited by
-
[Transcultural symptomatology. Its expression in family practice].Can Fam Physician. 1995 Oct;41:1718-25. Can Fam Physician. 1995. PMID: 8829582 Free PMC article. Review.
-
Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.J Clin Hypertens (Greenwich). 2023 Aug;25(8):661-688. doi: 10.1111/jch.14695. Epub 2023 Jul 7. J Clin Hypertens (Greenwich). 2023. PMID: 37417783 Free PMC article.
-
Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions.J Neurol. 2023 Nov;270(11):5251-5273. doi: 10.1007/s00415-023-11876-y. Epub 2023 Jul 21. J Neurol. 2023. PMID: 37477834 Review.
-
Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.Drugs. 1992 Mar;43(3):346-81. doi: 10.2165/00003495-199243030-00005. Drugs. 1992. PMID: 1374319 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical